{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000033","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-06-15T20:06:58+00:00","discovered_at":"2026-06-15T20:08:00.310339+00:00","generated_at":"2026-06-15T20:16:51.111846+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA accepts Inhibrx BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027","bullets":["FDA accepted BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma.","No filing review issues identified; PDUFA goal date set for April 14, 2027.","If approved, ozekibart would be first FDA-approved systemic therapy for this indication.","Pivotal ChonDRAgon trial showed 52% risk reduction in disease progression/death (HR 0.479; p<0.0001).","Median PFS 5.52 months for ozekibart vs 2.66 months for placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000033","json":"https://secwatch.observer/filing/0002007919-26-000033.json","markdown":"https://secwatch.observer/filing/0002007919-26-000033.md","text":"https://secwatch.observer/filing/0002007919-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/0002007919-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:16:51.111846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}